Immix Biopharma (IMMX) Projected to Post Quarterly Earnings on Friday

Key Points

• Immix Biopharma is expected to report Q2 2026 results after the market closes on August 14, with analysts projecting a loss of $0.17 per share. The company’s previous quarterly loss of $0.18 per share beat estimates by $0.01.
• IMMX shares opened at $10.06 and have gained 5.5%, trading well above their 52-week low of $1.94 but below the $12.14 high. Institutional investors own 11.26% of the company.
• Analyst sentiment is broadly positive, with eight Buy ratings, one Hold and one Sell, producing a “Moderate Buy” consensus and an average price target of $20.71 versus the current share price.

Immix Biopharma (NASDAQ:IMMX - Get Free Report) will likely be releasing its Q2 2026 results after the market closes on Friday, August 14th. Analysts expect the company to post earnings of ($0.17) per share for the quarter. Parties can check the company's upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Monday, August 10, 2026 at 4:00 PM ET.

Immix Biopharma (NASDAQ:IMMX - Get Free Report) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.01. On average, analysts expect Immix Biopharma to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Immix Biopharma Trading Up 5.5%

Shares of Immix Biopharma stock opened at $10.06 on Friday. The company has a market cap of $547.36 million, a P/E ratio of -10.93 and a beta of 0.11. The stock has a 50-day moving average price of $9.37 and a 200 day moving average price of $8.82. Immix Biopharma has a 1 year low of $1.94 and a 1 year high of $12.14.

Institutional Investors Weigh In On Immix Biopharma

Several large investors have recently made changes to their positions in IMMX. Balyasny Asset Management L.P. bought a new position in Immix Biopharma during the fourth quarter valued at approximately $67,000. Squarepoint Ops LLC bought a new stake in Immix Biopharma in the fourth quarter worth approximately $112,000. Quadrature Capital Ltd bought a new stake in Immix Biopharma in the fourth quarter worth approximately $116,000. Persistent Asset Partners Ltd acquired a new position in shares of Immix Biopharma during the 4th quarter worth $166,000. Finally, Hudson Bay Capital Management LP acquired a new position in shares of Immix Biopharma during the 4th quarter worth $176,000. Institutional investors own 11.26% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on IMMX. Citigroup began coverage on shares of Immix Biopharma in a research note on Thursday, June 18th. They issued a "buy" rating on the stock. Needham & Company LLC started coverage on shares of Immix Biopharma in a research report on Wednesday, July 22nd. They issued a "buy" rating and a $21.00 target price for the company. Weiss Ratings reissued a "sell (d-)" rating on shares of Immix Biopharma in a research note on Friday, July 17th. Bank of America began coverage on shares of Immix Biopharma in a report on Thursday, June 18th. They set a "buy" rating and a $27.00 price target on the stock. Finally, HC Wainwright upped their price target on shares of Immix Biopharma from $15.00 to $20.00 and gave the stock a "buy" rating in a research note on Friday, May 22nd. Eight investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $20.71.

About Immix Biopharma

Immix Biopharma NASDAQ: IMMX is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company's approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company's lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source